…
comment: The repository administrator has not yet configured an RDF license.
primary topic: Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin

Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin
type: AcademicArticle
type: Article
abstract: Background: Stenotrophomonas sepilia, identified in 2021, is part of the Stenotrophomonas maltophilia complex (Smc) and shares high genomic identity with S. maltophilia. Resistance to levofloxacin, the recommended fluoroquinolone for S. maltophilia, is being increasingly reported. Recent studies indicate that levonadifloxacin, a novel benzoquinolizine, may be more effective. This study evaluates the antimicrobial efficacy of levofloxacin and levonadifloxacin against clinical isolates of S. sepilia. Objectives: To assess the antibacterial effectiveness of levofloxacin and levonadifloxacin against novel pathogen S. sepilia. Methods: A total of 116 S. maltophilia isolates, identified by MALDI-TOF MS, were collected from five centres across India. S. sepilia was confirmed by PCR using primers targeting a unique genomic sequence (NCBI accession number LXXZ00000000.1). Minimum inhibitory concentrations (MICs) of levonadifloxacin and levofloxacin were determined by using the microbroth-dilution method and Etest as per CLSI guidelines. The levofloxacin breakpoint was used to interpret MICs of levonadifloxacin. Results: Among a total of 116 circulating S. maltophilia isolates collected, 46 were identified as S. sepilia, representing a prevalence rate of (â�¼40%), thus highlighting its significance as an important pathogen within the Smc. Both levofloxacin and levonadifloxacin demonstrated a 98% inhibition rate against the 46 S. sepilia tested. Only one S. sepilia isolate resistant to levofloxacin showed intermediate susceptibility to levonadifloxacin, which consistently had lower MICs. Conclusions: Levofloxacin and levonadifloxacin show similar susceptibility rates against S. sepilia, with levonadifloxacin exhibiting lower MICs. Further studies are required to establish clinical utility of levonadifloxacin in managing these infections.
date: 2024-08
volume: 6
issue: 4
author list: authors
type: EPrint
type: ArticleEPrint
is part of: repository

Oxford University Press (OUP)
type: Organization

JAC Antimicrob. Resist.
type: Collection

Ekadashi Rajni
type: Person
given name: Ekadashi
family name: Rajni

Nishant Shekhar
type: Person
given name: Nishant
family name: Shekhar

Vikas Gautam
type: Person
given name: Vikas
family name: Gautam

Lipika Singhal
type: Person
given name: Lipika
family name: Singhal

Ivneet Kour
type: Person
given name: Ivneet
family name: Kour

Suneeta Sahu
type: Person
given name: Suneeta
family name: Sahu

Rajneesh Singh Rawat
type: Person
given name: Rajneesh Singh
family name: Rawat

Rahul K Verma
type: Person
given name: Rahul K
family name: Verma

Sanjay Biswas
type: Person
given name: Sanjay
family name: Biswas

Prabhu B Patil
type: Person
given name: Prabhu B
family name: Patil

Surajit Chakraborty
type: Person
given name: Surajit
family name: Chakraborty

Kanika Bansal
type: Person
given name: Kanika
family name: Bansal

Ajay Duseja
type: Person
given name: Ajay
family name: Duseja

HTML Summary of #3305 Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin
format: text/html
primary topic: Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin